Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of crmp2 and anti-crmp2 antibody

An antibody and reagent technology, applied in the application field of CRMP2 and anti-CRMP2 antibodies, can solve problems such as unclear mechanism

Active Publication Date: 2021-12-28
NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
View PDF15 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, LG1 encephalitis and many AEs, especially young patients, have neither tumor discovery nor evidence of early viral infection in long-term follow-up, so the explanation mechanism is mostly unclear, and the mechanism of AE needs to be further studied

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of crmp2 and anti-crmp2 antibody
  • Application of crmp2 and anti-crmp2 antibody
  • Application of crmp2 and anti-crmp2 antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] The numbers of the 3 patients in this example are: P1, P2, and P3, respectively.

[0044] P1 was the first case, and CRMP2 was identified by its cerebrospinal fluid and blood samples; P2 and P3 were positive cases of anti-CRMP2 antibody detected by retrospective analysis of CBA method.

[0045] P1, P2, and P3 all had symptoms of dizziness or headache, visual impairment, and unsteady walking; white matter lesions; immunotherapy was effective; blood and / or cerebrospinal fluid in rat brain slices were positive for TBA; anti-CRMP2 antibody was positive for other AEs Antibody tests were negative.

[0046] P1 and P3 had language barriers, bilateral finger-to-nose tests were inaccurate; P2 had chest and abdomen pain, and spinal cord lesions.

[0047] P1 cerebrospinal fluid was positive for Mycoplasma pneumoniae; P3 cerebrospinal fluid was positive for human herpesvirus 6 and Klebsiella pneumoniae; blood was positive for influenza B virus IgM.

[0048] The specific clinical d...

Embodiment 2

[0056] Immunohistochemical experiments based on rat brain slices are routine examinations for autoimmune encephalitis, including immunoenzyme chemistry and immunofluorescence (also known as TBA, tissue based assay).

[0057] Implementation process: perfuse the heart of an adult rat with PBS (phosphate buffered saline) after anesthesia to remove circulating blood, take the brain (including the hippocampus) for sagittal frozen section, take the cerebellum for longitudinal section, fix it in cold acetone for 10 minutes, and let it dry Dry and set aside. The slices were washed 3 times with PBST solution (PBS containing 0.05% Tween-20), 3 minutes each time.

[0058] Next, carry out immunoenzyme chemistry method and immunofluorescence method respectively to detect: (1) Carry out immunoenzyme chemistry method: treat with 3% hydrogen peroxide again for 10 minutes, wash 3 times with PBST and carry out next step blocking, use 10% goat serum / PBST solution at room temperature for blocki...

Embodiment 3

[0064] Identification of antigens targeted by autoantibodies in cerebrospinal fluid of P1 patients using immunoprecipitation combined with protein profiling.

[0065] Implementation process: take fresh brain tissue of about 2-month-old rats, add 1 ml protein lysate (20mmol / L Tris-HCl, pH 7.4, 150mmol / L NaCl, 2mmol / L EDTA, 1% TritonX-100, protease inhibitor ), homogenized for 1 minute with a glass homogenizer, and lysed on ice for 30 minutes. Centrifuge at 12,000 rpm at 4°C for 15 minutes, and take the supernatant as rat brain protein lysate. Mix 500 microliters of protein lysate with 500 microliters of cerebrospinal fluid of P1 patient, and vortex vertically at 4°C overnight. Add 50 μl of pre-washed protein A-labeled agarose, and vortex vertically at 4°C for 2 hours. Centrifuge at 4°C, 1000rpm, resuspend, rinse with protein lysate 3 times, then add 1xSDS-PAGE sample buffer, boil for 5 minutes to elute the protein complex. The prepared samples were separated by SDS-PAGE, fol...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of CRMP2 and anti-CRMP2 antibodies, specifically the application of CRMP2 and / or anti-CRMP2 antibodies as markers for nervous system autoimmune diseases, and the preparation of reagents for detecting anti-CRMP2 antibodies in the detection of nervous system autoimmune diseases , application in diagnostic, therapeutic or prognostic assessment reagents. The present invention discovers through research that CRMP2 is a new encephalitis / encephalomyelitis-related autoantibody targeting molecular marker. CRMP2 can be used for the definite diagnosis of the disease and provide evidence for the immunotherapy plan, and can monitor the therapeutic effect and judge the prognosis and recurrence by detecting the titer change of the autoantibody.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the application of CRMP2 and anti-CRMP2 antibodies. Background technique [0002] Nervous system autoimmune disease is a type of disease caused by autoimmune molecules and immune cells recognizing the components of nervous system tissue cells (autoantigens) and causing inflammation and other damage. It can occur in the central nervous system, peripheral nervous system and nerve-muscle Joints, including: autoimmune encephalitis (autoimmune encephalitis, AE), central demyelinating diseases, autoimmune peripheral neuropathy, etc. Among them, AE is the most common, clinically manifested as acute or subacute onset (<3 months), with one or more neurological and psychiatric symptoms or clinical syndromes: 1) limbic system symptoms: recent memory loss, seizures, Abnormal mental behavior; 2) encephalitic syndrome: clinical manifestations of diffuse or multifocal brain ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/564G01N33/68A61K45/00A61P25/00A61P29/00A61P37/02
CPCG01N33/564G01N33/6854G01N33/6893A61K45/00A61P37/02A61P25/00A61P29/00G01N2800/24G01N2800/28G01N2800/52A61K31/713C07K16/18A61K45/06C12N15/63
Inventor 潘速跃胡亚芳刘光辉王胜男王冬梅徐凯彪吴永明
Owner NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV